Recently, gene expression microarray analysis demonstrated that Burkitt's lymphoma displays a characteristic genetic signature. 6, 7 It was found that CD44 is constantly downregulated on the mRNA level in Burkitt's lymphoma when compared with DLBCL patients. CD44 is a cell surface protein that is the principal receptor for hyaluronate, plays a pivotal role in cell adhesion and migration and is correlated to the metastatic potential of several hematological malignancies. We have shown previously that its level of expression increases with maturation of normal BCP cells in the BM. 4 Sequential stages of BCP cells are usually assumed to correspond to the different subtypes of B-cell lymphoid malignancies of childhood. In particular, Burkitt's lymphoma/leukemia cells have many features in common with normal surface IgM þ BCP cells, which express high levels of CD44. Hence, we questioned whether the expression patterns of CD44 in normal BCP stages are also conserved in childhood Burkitt's lymphoma and leukemia or whether significant CD44 expression is lacking on the tumor cells as could be deduced from the microarray analyses.
Between January 1994 and November 2006, 133 Austrian children and adolescents up to 19 years of age with mature B-cell neoplasms (Burkitt's lymphoma/leukemia, n ¼ 87; nonBurkitt's NHL, n ¼ 38) and BCP LBL (n ¼ 8) were enrolled in either of the contemporarily performed Berlin-Frankfurt-Mü nster (BFM) multicenter trials of childhood NHL. 8 For our study 4, 5 We recorded the intensity of antigen expression (mean fluorescence intensity, MFI) based on determining the median channel value of the investigated cell population. Conventional cytogenetic procedures were carried out according to standard protocols. Fluorescence in situ hybridization (FISH) analysis was applied using the commercial tri-color-labeled LSI IGH/MYC,CEP8 probe set (Vysis, Downers Grove, IL, USA) according to the manufacturer's recommendation to detect an IGH/C-MYC rearrangement.
Among the 21 patients with Burkitt's lymphoma, the diagnosis was based on a combination of typical histopathology, FAB L3 cytomorphology and mature (surface IgM þ ) B-cell immunophenotypes. Similarly, in all 18 patients with Burkitt's leukemia, the diagnosis was established by FAB L3 cytomorphology and a mature B-cell phenotype of BM blasts. In detail, diagnostic material used for cytomorphologic and immunophenotypic analyses of the lymphoma patients was malignant effusions in 10/21 (pleural effusion, n ¼ 6; ascites, n ¼ 4), tumor touch imprints/cell suspensions in 8/21, BM in 2/21 and cerebrospinal fluid in 1/21 patients. In 5/21 patients, no solid tumor material was obtained and evaluated for histopathology, as guidelines of the sequential NHL-BFM protocols allowed the diagnosis of Burkitt's lymphoma with cytomorphologic and immunophenotypic results alone. In 10/21 patients, conventional cytogenetics showed a t(8;14)(q24;q32) and in another patient a t(8;22)(q24;q11). In further 7/21 patients, FISH analysis demonstrated the presence of an IGH/C-MYC fusion gene. Among the remaining three patients, one had a normal karyotype, whereas cytogenetic or FISH analyses were not performed in 2/21 patients. In 13/18 patients with Burkitt's leukemia, conventional cytogenetics on BM blasts showed a t(8;14)(q24;q32). In another patient, FISH analysis found an IGH/C-MYC rearrangement, whereas 2/18 cases displayed a normal karyotype and other 2/18 patients had no metaphases to be analyzed.
Among the five patients with BCP LBL, the diagnosis was established by a combination of typical histopathology, FAB L1/ L2 cytomorphology and BCP phenotypes. Diagnostic material for immunophenotyping included tumor cell suspensions in three and BM blasts in two patients (both with stage IV disease). Immunophenotypic subclassification revealed a common (CD10 þ ) BCP phenotype in two patients and a pre-B (cytoplasmic IgM þ ) cell phenotype in three patients. Among the four patients with DLBCL studied, cytomorphologic and immunophenotypic analyses of tumor touch imprints and cell suspensions were compatible with a mature B-cell-derived large-cell lymphoma. Definite diagnosis was established by histopathology.
Regarding CD44 expression, all 21/21 patients with Burkitt's lymphoma and 17/18 patients with Burkitt's leukemia were aberrant as defined by the absence of the antigen (geo-MFI o50) ( Figure 1 ). The median MFI of CD44 was five (range 2-21) for the Burkitt's lymphoma and 6.5 (range 2-105) for the Burkitt's leukemia patients, respectively. Moreover, the ratio between the median MFI of the tumor cells and the residual non-tumor surface IgM þ BCP cells found within the diagnostic samples was 1:250 for the Burkitt's lymphoma and 1:99 for the leukemia patients. Since Burkitt's cells may rapidly undergo apoptosis ex vivo, we evaluated whether freshness of materials may have influenced our findings. However, the ratio between the median MFI of the Burkitt's lymphoma/leukemia cells and the normal surface IgM þ BCP cells in specimens analyzed immediately after sampling in our own institution (n ¼ 21; 1:153, median 6 vs 1012) was not different when compared to the samples received after overnight transport at ambient temperature from other centers (n ¼ 18; 1:169, median 5 vs 767).
Four Overall, cases of Burkitt's lymphoma/leukemia (n ¼ 39) showed a statistically significant absence of the CD44 antigen, when compared with the patients with non-Burkitt's lymphoma (n ¼ 9) (w 2 : Po0.001). The sensitivity of an absence of CD44 expression for the diagnosis of Burkitt's lymphoma and leukemia therefore was 97% (n ¼ 38/39). Nevertheless, with respect to the single case of non-Burkitt's lymphoma included in our series that lacked CD44, it should be noted that aberrant CD44 deficiency cannot be considered as an exclusive hallmark of Burkitt-type neoplasms. It has also been shown to occur in some cases (7%) of immature BCP ALL. 4 Two recently published articles have given compelling evidence that by using gene expression microarray technology, the diagnostic accuracy of Burkitt's lymphoma is enhanced clearly. 6, 7 This finding is especially essential in adult oncology, as Burkitt's lymphoma and most subtypes of DLBCL are usually treated by protocols of different intensity. However, microarray analysis is not yet a commonly available tool for daily diagnostic routine. By contrast, immunophenotyping by flow cytometry is broadly established and a rapid method for diagnostic purposes in clinical practice. Besides other biomarkers (MUM1-, TCL1 þ , HLA-I-, CD23-and Cyclin H-) Dave et al. 7 and Hummel et al. 6 found downregulation of CD44 on the mRNA level in their series of Burkitt's lymphomas studied. We now extend this observation by demonstrating that Burkitt's lymphoma/leukemia cases also lack CD44 on the protein level by investigating its cell surface expression. Accordingly, this gross divergence to normal BCP cells may be exploited for the sub-microscopical detection of rare Burkitt's lymphoma cells in the BM or peripheral blood by using flow cytometry ( Figure 2 ). In sight of the poor survival rates of children and adolescents with relapsed Burkitt's lymphoma, the identification of new prognostic markers such as MDD or MRD could thus aid in refining risk stratification and in identifying patients with a higher risk of relapse already at the early stages of treatment. In addition to PCR-based technologies taking the advantage of clonal gene rearrangements, based on our findings, flow cytometry may represent another fruitful and particularly rapid approach to MDD and MRD assessment in Burkitt's neoplasms. Although we found no impact of time delay between sampling and immunophenotyping on the expression levels of CD44, stabilization of the samples for transport will be very important to avoid loss of residual Burkitt's cells, which are especially prone to undergo spontaneous apoptosis. 9 In summary, we found that childhood Burkitt's lymphoma/ leukemia is typically CD44-deficient, which contrasts with the expression patterns found in normal B-cell stages of comparable maturity and in other B-cell-derived lymphoid malignancies. This peculiarity may eventually allow the detection of rare tumor cells at a sub-microscopical level not only at the time of diagnosis but also during the initial phase of treatment. Abnormalities of chromosome 1 are among the most frequent chromosomal alterations in multiple myeloma (MM), being found in up to 45% of patients. 1,2 It has been reported that the short arm of chromosome 1 is preferentially involved in deletions, whereas the long arm is associated with amplification. The gain of 1q (1q/gain) can occur as isochromosomes, duplications or jumping translocations. It has been widely reported that 1q/gain MM patients are characterized by complex karyotypes and aggressive disease, and a close association with poor-risk genetic features, such as chromosome 13q deletion (D13) and the t(4;14) translocation has also been described. 1 It has been recently demonstrated that gains/amplification of 1q21 increase as the condition goes from smoldering to overt MM, thus suggesting that these regions contain critical genes for disease progression.
2 These findings along with the limited information concerning specific transcriptional profiles prompted us to molecularly characterize 1q/gain MMs by FISH and microarray analyses.
Our study includes a panel of 77 MM patients at diagnosis, whose characteristics have been deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO; http://www.ncbi.nlm.mih.gov/geo, accession number GSE6401). Bone marrow plasma cells were purified (490% in all cases) using CD138-immunomagnetic bead selection and characterized by FISH for the presence of 11 polisomy, the most recurrent IGH translocations, ploidy status, D13, and global gene expression profiling using the Affymetrix U133A gene chips, as described previously. 3 Patients were then stratified accordingly to the proposed translocation/cyclin D (TC) classification in five groups: TC1 characterized by the t(11;14) or t(6;14) translocations, with the consequent overexpression of either CCND1 or CCND3, and a nonhyperdiploid status; TC2 showing low/moderate levels of the CCND1 gene in the absence of any primary IGH translocations, and a hyperdiploid status; TC3 including tumors that do not fall into any of the other groups, most of which express CCND2; TC4 showing high CCND2 levels and the presence of the t(4;14) translocation and TC5 expressing the highest levels of CCND2 in association with either the t(14;16) or t(14;20) translocation. 3 Assessment of 1q/gain by FISH was performed by using three BAC clones specific for the BCL9 (1q21.1), CKS1B (1q22) and ARF1 (1q42.13) loci, and setting the threshold as 10%. Specific alterations were identified in 40/77 (51.9%) patients; three (75%) or four (12.5%) signals of all the 1q probes were found in 35 patients and, in the remaining five samples (12.5%), the probes mapping to 1q21 and 1q22 showed more signals than that mapping to 1q42. 1q/gain was observed in the majority of purified plasma cells (490%) in all but three patients (range 12-20%). 1q/gain was significantly absent in TC2 group (Po10 À4 ) and present in TC3 (P ¼ 0.008), whereas the correlation was not significant in the TC1 (P ¼ 0.053) or TC4 (P ¼ 0.142) groups; in addition, 1q extra copies significantly associated with D13 (Po10
À4
) and chromosome 11 polisomy (although at a limited significance level of P ¼ 0.038), but not ploidy status (P ¼ 0.0971).
To identify a specific transcriptional fingerprint characterizing 1q/gain, we made a supervised analysis of 1q/gain versus 1q/ normal MM patients using SAM algorithm. Seventy-two probe sets (specific for 61 genes) distinguished the 40 1q/gain from the 37 1q/normal cases ( Figure 1a and Table 1a, b) . Notably, in the 1q/gain patients 41 of the 43 upregulated genes mapped to 1q12-q44, whereas a significant percentage of the downregulated genes was localized on chromosomes 13q (7/18; 39%) and 11 (6/18, 33%). To verify whether the 1q/gain reflected transcriptional imbalances of specific chromosomal regions, the expression data from the 1q/gain and 1q/normal samples were also analyzed in the context of the physical localization of the genes using a model-free statistical method (LAP), 4 allowing the identification of five modulated chromosomal regions (Figure 1b) . In the 1q/gain patients, the region 1q21.1-q44 (absolute positions: 146,567,360-245,353,955) was upregulated and 13q12-14 (22,800,966-47,961,101) downregulated, which is in line with the significant association
